Marktanalyse - Constipation - Pipeline Review, H1 2017

Global Markets Direct
02.2017
108 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Constipation - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Constipation — Pipeline Review, H1 2017, provides an overview of the Constipation (Gastrointestinal) pipeline landscape.

Constipation refers to the infrequent or difficult passing of stool. Constipation occurs when bowel movements become difficult or less frequent. Symptoms of constipation include swollen abdomen or abdominal pain, pain and vomiting. The predisposing factors include eating disorders, irritable bowel syndrome, and hypothyroidism, overuse of laxatives (stool softeners) which, over time, weaken the bowel muscles, stress, inadequate water intake and inadequate fiber in the diet. Treatment includes use of laxatives and proper lifestyle.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Constipation — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Constipation (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Constipation (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Constipation and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 7, 8, 2, 3 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Constipation (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Constipation (Gastrointestinal).
- The pipeline guide reviews pipeline therapeutics for Constipation (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Constipation (Gastrointestinal) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Constipation (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Constipation (Gastrointestinal)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Constipation (Gastrointestinal).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Constipation (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Constipation - Overview

Constipation - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Constipation - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Constipation - Companies Involved in Therapeutics Development

Albireo Pharma Inc

Ardelyx Inc

Assembly Biosciences Inc

Astellas Pharma Inc

Braintree Laboratories Inc

CJ HealthCare Corp

Dong-A Socio Holdings Co Ltd

EA Pharma Co Ltd

Ironwood Pharmaceuticals Inc

Lipid Pharmaceuticals ehf

Motus Therapeutics Inc

NGM Biopharmaceuticals Inc

RaQualia Pharma Inc

Sanwa Kagaku Kenkyusho Co Ltd

Shire Plc

SK Biopharmaceuticals Co Ltd

Sucampo Pharmaceuticals Inc

Sumitomo Dainippon Pharma Co Ltd

Synthetic Biologics Inc

Torrent Pharmaceuticals Ltd

Yuhan Corp

Constipation - Drug Profiles

5-BIOP - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AJG-555 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-7663 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Irritable Bowel Syndrome with Constipation - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLI-400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLI-801 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJ-14199 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DA-6886 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DSP-6952 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

elobixibat - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ENT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

J-027 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

linaclotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lovastatin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lubiprostone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naronapride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGM-282 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prucalopride succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

prucalopride succinate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relamorelin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

relenopride hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RQ-00000010 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SK-1202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tenapanor hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

YH-12852 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Constipation - Dormant Projects

Constipation - Product Development Milestones

Featured News & Press Releases

Feb 01, 2017: Albireo Announces Submission of New Drug Application for Elobixibat in Japan

Jan 30, 2017: Astellas and Ironwood Report Positive Top-Line Results from Phase III Linaclotide Trial for Patients with Chronic Constipation Conducted in Japan

Jan 26, 2017: U.S. Food and Drug Administration Approves 72 mcg Dose of LINZESS (linaclotide) for Adults with Chronic Idiopathic Constipation

Dec 22, 2016: Ironwood and Allergan Report Topline Phase IIb Data Supporting Advancement of Linaclotide Colonic Release-1 (CR1) in IBS-C

Nov 16, 2016: Renexxion Achieves Positive FDA Guidance for Phase 3-ready GI Drug Naronapride

Oct 19, 2016: Ardelyx Announces the Presentation of Positive Global Endpoint Findings from Phase 2b Trial of Tenapanor in Patients with IBS-C at ACG Annual Meeting

Oct 03, 2016: Albireo Announces Positive Top-Line Phase 3 Results for Elobixibat in Japan

Sep 30, 2016: EA Pharma and Mochida Pharmaceutical Announce the Results of Phase 3 Study of AJG533 for Chronic Constipation Conducted in Japan

Aug 19, 2016: The First Dosing of RQ-00000010 at Virginia Commonwealth University Initiated

Aug 02, 2016: Synthetic Biologics Announces Completion of End of Phase 2 Meeting with FDA for SYN-010, Intended for the Treatment of Irritable Bowel Syndrome with Constipation

Jun 09, 2016: Ironwood and Allergan Announce Supplemental New Drug Application for 72 mcg Linaclotide in Chronic Idiopathic Constipation Has Been Accepted for FDA Review

May 23, 2016: Synthetic Biologics Announces Detailed Data from Two SYN-010 Phase 2 Clinical Trials for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

May 17, 2016: Ironwood Pharmaceuticals to Present Linaclotide Data at Digestive Disease Week 2016

May 17, 2016: Synthetic Biologics to Host Post-DDW 2016 Conference Call to Recap SYN-010 Phase 2 Clinical Trial Results for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)

May 11, 2016: Isaac J. Bright, MD, Joins Synthetic Biologics as Vice President, Corporate Development

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer





List of Tables

Number of Products under Development for Constipation, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Constipation - Pipeline by Albireo Pharma Inc, H1 2017

Constipation - Pipeline by Ardelyx Inc, H1 2017

Constipation - Pipeline by Assembly Biosciences Inc, H1 2017

Constipation - Pipeline by Astellas Pharma Inc, H1 2017

Constipation - Pipeline by Braintree Laboratories Inc, H1 2017

Constipation - Pipeline by CJ HealthCare Corp, H1 2017

Constipation - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Constipation - Pipeline by EA Pharma Co Ltd, H1 2017

Constipation - Pipeline by Ironwood Pharmaceuticals Inc, H1 2017

Constipation - Pipeline by Lipid Pharmaceuticals ehf, H1 2017

Constipation - Pipeline by Motus Therapeutics Inc, H1 2017

Constipation - Pipeline by NGM Biopharmaceuticals Inc, H1 2017

Constipation - Pipeline by RaQualia Pharma Inc, H1 2017

Constipation - Pipeline by Sanwa Kagaku Kenkyusho Co Ltd, H1 2017

Constipation - Pipeline by Shire Plc, H1 2017

Constipation - Pipeline by SK Biopharmaceuticals Co Ltd, H1 2017

Constipation - Pipeline by Sucampo Pharmaceuticals Inc, H1 2017

Constipation - Pipeline by Sumitomo Dainippon Pharma Co Ltd, H1 2017

Constipation - Pipeline by Synthetic Biologics Inc, H1 2017

Constipation - Pipeline by Torrent Pharmaceuticals Ltd, H1 2017

Constipation - Pipeline by Yuhan Corp, H1 2017

Constipation - Dormant Projects, H1 2017





List of Figures

Number of Products under Development for Constipation, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus